A Novel Tumor Suppressor ASMTL-AS1 Regulates the Mir-1228-3p/SOX17/β-Catenin Axis in Triple-Negative Breast Cancer

Jie Sun
Soochow University Affiliated No 1 People’s Hospital: First Affiliated Hospital of Soochow University

Xiaohua Li
Soochow University

Enqiao Yu (enqiao_yu@163.com)
Soochow University

Jianxia Liu
Soochow University

Liang Sun
Soochow University

Qin He
Soochow University

Qiran Lu
Soochow University

Research

Keywords: ASMTL-AS1, TNBC, Wnt/β-catenin pathway, miRNA sponges, prognosis

Posted Date: March 18th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-333526/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Triple-negative breast cancer (TNBC) is a special type of breast cancer that lacks effective therapeutic targets. There is a significant need to clarify its pathogenesis, so as to bring new targeted approaches for TNBC management. Here, we identified a long-non coding RNA (lncRNA) ASMTL-AS1 that linked to TNBC development and progression.

**Methods:** Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays were used to test gene and protein levels, respectively. The regulatory axis of miR-1228-3p/FOX17/β-catenin was determined by luciferase reporter and RNA pull-down assays. In vivo assay was conducted by using the nude mice model via subcutaneous transplantation of tumor cells.

**Results:** ASMTL-AS1 was significantly downregulated in TNBC tissues compared to normal tissues, which was closely associated with aggressive clinical features and unfavorable prognosis. Lentivirus-mediated ASMTL-AS1 overexpression evidently inhibited TNBC cell colony formation, viability and invasion. RNA pull-down and luciferase reporter assays revealed that miR-1228-3p was the downstream target of ASMTL-AS1, ASMTL-AS1 increased SOX17 expression via sponging and repressing miR-1228-3p. Subsequently, the upregulated SOX17 trans-suppressed β-catenin expression, resulting in the inactivation of carcinogenic Wnt/β-catenin signaling, thereby restraining TNBC cell growth and dissemination. Importantly, the xenograft tumor model showed that the ASMTL-AS1/miR-1228-3p/FOX17/β-catenin regulatory axis was indeed existed in vivo.

**Conclusion:** Our data characterize a novel tumor suppressor in TNBC, restoration of ASMTL-AS1 may be a candidate therapeutic intervention for TNBC patients.

**Background**

Breast cancer has now overtaken lung cancer as the leading cause of cancer incidence worldwide, with an estimated 2.3 million new cases, accounting for 11.7% of all cancer cases[1]. As a specific subtype of breast cancer, triple-negative breast cancer (TNBC) is characterized by negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2), accounting for about 15 ~ 20% of all breast cancer cases[2]. Chemotherapy is the main treatment for TNBC, such as paclitaxel and platinum drugs and so on, while targeted and endocrine therapy are basically ineffective[3]. However, chemotherapy drugs have no selectivity, while killing cancer cells, they will also cause damage to normal cells, causing some adverse reactions[4]. Therefore, in-depth study of the etiopathogenesis of TNBC in order to find effective therapeutic targets has become a research hotspot in the current medical field.

Long non-coding RNA (lncRNA) is a kind of endogenous RNA with transcripts longer than 200nt, which was previously thought to be the "noise" of transcriptome, with no definite biological function[5]. In recent years, with the deepening of research, more and more evidence shows that lncRNA participates in individual growth, development and cell differentiation, and acts as a crucial regulator of gene expression at the transcriptional and post-transcriptional levels[6, 7]. LncRNA is frequently abnormally expressed in human cancer tissues, and is widely involved in many important regulatory processes, such as chromatin modification, transcriptional activation and interference and intranuclear transport, closely linking to cancer occurrence and development[8]. One of the main functions of lncRNA is adsorption of microRNAs (miRNAs), in which lncRNA competitively binds to miRNAs, relieving the suppressive effect of miRNA on target genes, this model is also known as "competing endogenous RNA (ceRNA)" network[9]. Extensive studies have shown that lncRNA serves as a ceRNA in various human diseases, such as the lnc-BCYRN1/miR-619-5p/CUEDC2 axis in glioma[10], Inc-DM3OS/miR-126/IGF1 axis in osteoarthritis[11], and Inc-UCA1/miR-182-5p/DLL4 axis in renal cancer[12].

ASMTL-AS1 is a newly found lncRNA that locates at Xp22.33 and Yp11.2, which has been recently reported as a key player in papillary thyroid cancer[13] and hepatocellular carcinoma[14], and could be used as a prognostic biomarker for bladder cancer[15]. Nevertheless, its role in TNBC remains unknown. In this study, we aimed to explore the expression, function and clinical implication of ASMTL-AS1 in TNBC, furthermore, we also uncovered the tumor-inhibiting role of ASMTL-AS1 by acting as a ceRNA.

**Methods**

**Tissue samples and cell lines**

This study was approved by the medical ethics committee of The 1st Affiliated Hospital of Soochow University, which was conducted in strict accordance with the Helsinki Declaration. The matched TNBC and para-cancerous normal tissues were collected from 68 TNBC patients undergoing surgical resection at The 1st Affiliated Hospital of Soochow University. We obtained informed consent from all patients, and the clinicopathological features were displayed in Table 1. Two TNBC cell lines MDA-MB-231 and MDA-MB-468 were purchased from ATCC, cultured in RPMI-1640 medium, and stored in liquid nitrogen vapor phase at -80°C.

**qRT-PCR analysis**

Total RNA of tissues and cells was extracted by Trizol solution (Invitrogen, CA, USA), and RNA with different subcellular localization was separated by Cytoplasmic & Nuclear RNA Purification Kit as per supplier's instructions (Norgen Biotek, ON, Canada). Then, the single-stranded cDNA was synthesized by GOScript™ reverse transcriptase (Promega, WI, USA), followed by quantification with GoTaq® qPCR Master Mix by 2^ΔΔCt method. U6 and GAPDH were used as reference controls for nuclear and cytoplasmic fragments, respectively.

**Generation of stable ASMTL-AS1-overexpressing cell lines**
The full-length sequence of ASMTL-AS1 was synthesized and cloned into pLCDH-CMV-MCS-EF1-GFP-Puro lentiviral vector. Then, MDA-MB-231 and MDA-MB-468 cells were infected with above lentiviral vector in the presence of 5μg/mL polybrene. Cells were routinely cultured in RPMI-1640 medium added with 1μg/mL puromycin for 1 week. qRT-PCR analysis was applied to verify the infection efficiency.

**Colony formation and CCK-8 assays**

500 MDA-MB-231 and MDA-MB-468 cells were seeded into 6-well plates, then routinely cultured in RPMI-1640 medium for 2 weeks. Cells were washed by PBS twice and fixed by methanol, the number of clones was observed under a light microscope. For testing cell viability, 1×10^4 cells were seeded into 96-well plates and cultured for 72h. 10μL CCK-8 reaction solution (Dojindo, Kumamoto, Japan) was added every 24h and incubated at 37°C for 1h. The absorbance at 450nm was recorded by a microplate reader.

**Transwell assay**

5×10^4 MDA-MB-231 and MDA-MB-468 cells in 200μL RPMI-1640 medium were added into upper Boyden chambers (BD Inc., CA, USA) coated with matrigel, while 600μL RPMI-1640 medium was added into lower chambers. After incubation at 37°C for 24h, the cells on the lower surface of the filter were fixed, stained and examined using a light microscope.

**RNA pull-down assay**

For affinity pull down of endogenous ASMTL-AS1, the biotin-labeled DNA probe complementary to ASMTL-AS1 was synthesized (Sangon, Shanghai, China) and incubated with TNBC cell lysates for 3h at 4°C. Then, the Dynabeads M-280 Streptavidin beads (Invitrogen) was added into above cell lysates and incubated for 0.5h at room temperature. RNA complexes were washed and eluted for qRT-PCR analysis of miRNA enrichment.

**Luciferase reporter assay**

The sequences of ASMTL-AS1 and SOX17 3’-UTR containing miR-1228-3p binding site were cloned into the downstream of FL reporter vector (Obio, Shanghai, China). Then, the reporter vector was co-transfected with pRL-CMV Renilla luciferase reporter and miR-1228-3p mimics into TNBC cells using Lipofectamine 2000 (Invitrogen). After 48h, the luciferase activity was tested by using the dual-luciferase reporter assay system (Promega).

**Western blot**

Total protein was extracted by the mammalian protein extraction kit (CWBO, Beijing, China) and quantified using the bicinchoninic acid (BCA) protein assay kit (CWBO) following manufacturer's instructions. Then, 10μg protein was loaded into the SDS-PAGE gel and transferred onto PVDF membrane. After blocking with 5% defatted milk powder for 30min at room temperature, the membrane was incubated with primary and secondary antibodies. The protein signal was visualized using the Immobilon-Western HRP kit (Millipore) and exposed to X-ray films. The primary antibodies used in this study are as follows: anti-SOX17 (#81778, CST), anti-SOX17 (#8480, CST) and anti-Tubulin (#2148, CST).

**Xenograft tumor experiment**

A total of 6 nude mice were randomly divided into two groups, pLCDH-vector and pLCDH-ASMTL-AS1. 1×10^7 control or ASMTL-AS1-overexpressing MDA-MB-231 cells were subcutaneously injected into nude mice. Tumor volume was measured every weeks by using a vernier caliper and calculated with length×width^2/2 formula. After 5 weeks, tumor tissues were collected and weighted. Total RNA was extracted by Trizol solution, followed by qRT-PCR analysis.

**Data analysis**

The average between the two groups was analyzed by Student’s t test, while Chi-square test was used to compare the categorical data, respectively. The survival curve was plotted by Kaplan-Meier method and analyzed by Log-rank test. P<0.05 was set as statistically significant.

**Results**

**ASMTL-AS1 is a downregulated IncRNA in TNBC**

First, we analyzed that expression of ASMTL-AS1 in GSE45827 GEO database containing 41 TNBC and 11 normal tissues, the results showed that ASMTL-AS1 was evidently decreased in TNBC tissues (Figure 1A). Then, we verified this downregulation in our cohort containing 68 pairs of TNBC and adjacent normal tissues (Figure 1B). Further, the correlations between ASMTL-AS1 and clinical features of TNBC patients were analyzed. As shown in Table 1, low ASMTL-AS1 level was positively associated with larger tumor size, lymph node metastasis and advanced TNM stage, but not with age and menopause status. Importantly, patients with high ASMTL-AS1 had longer overall survival time than those with low ASMTL-AS1 (Figure 1C). Consistently, the survival data from Kaplan-Meier plotter online tool showed that ASMTL-AS1 expression was reversely correlated with overall, recurrence-free and distant metastasis-free survival rate (Figure 1D-F). These data suggest that ASMTL-AS1 may be a protective IncRNA against TNBC.

**Exogenous overexpression of ASMTL-AS1 inhibits TNBC cell proliferation and invasion**

We constructed two ASMTL-AS1-overexpressing TNBC cell lines via infection of lentiviral vector into MDA-MB-231 and MDA-MB-468 cells (Figure 2A). Then, a series of functional assays were carried out. As shown in Figure 2B, C, ASMTL-AS1 overexpression resulted in a significant decreased in cell colony formation. CCK-8 assay showed that cell viability was weakened in ASMTL-AS1-overexpressed MDA-MB-231 and MDA-MB-468 cells as compared to control cells (Figure
2D, E). Likewise, Transwell assay showed that the number of invasive cells was substantially decreased after enforced expression of ASMTL-AS1 (Figure 2F, G).

**ASMTL-AS1 sponges miR-1228-3p in TNBC cells**

Through subcellular localization analysis, we found that ASMTL-AS1 was dominantly located in the cytoplasm (Figure 3A), hinting that it may be a ceRNA sponging miRNAs. The intersection result of three online tools showed that there are three miRNAs (miR-141-5p, miR-1228-3p and miR-4689) sequences complementary to ASMTL-AS1 (Figure 3B). We performed RNA pull-down assay to enrich endogenous miRNAs bound by ASMTL-AS1, the results showed that only miR-1228-3p was significantly pulled down by ASMTL-AS1 probe in both MDA-MB-231 and MDA-MB-468 cells (Figure 3C). Then, the binding site between ASMTL-AS1 and miR-1228-3p was mutated (Figure 3D), followed by luciferase reporter assay. The results displayed that miR-1228-3p overexpression significantly reduced the luciferase activity of the wild-type reporter, but did not affect the mutant one (Figure 3E). And miR-1228-3p expression was dramatically decreased in ASMTL-AS1-overexpressed TNBC cells in comparison to control cells (Figure 3F). These data indicate that ASMTL-AS1 is a ceRNA sponging miR-1228-3p in TNBC.

**ASMTL-AS1 represses Wnt/β-catenin signaling via the miR-1228-3p/SOX17 axis**

Through analyzing miRWalk online tool containing 8 prediction software, we found that SOX17, a transcription factor negatively regulating β-catenin expression, has the greatest possibility to be the downstream target gene of miR-1228-3p. We also mutated the complementary sequence between miR-1228-3p and SOX17 3’-UTR, leading to upregulated SOX17, which bound to β-catenin promoter and inhibited β-catenin activation. Pre-clinically, we found that low ASMTL-AS1 was closely related to aggressive clinical features as well as dismal survival, and could be used as a promising prognostic biomarker for TNBC. Therefore, our data highlight the importance of ASMTL-AS1 in inhibiting TNBC development and progression, and also identify a novel regulator of Wnt/β-catenin pathway (Figure 4G, H).

**ASMTL-AS1 overexpression retards TNBC cell proliferation in vivo**

Lastly, we explored the in vivo function of ASMTL-AS1 using xenograft tumor model. As shown in Figure 5 A, B, tumors induced by ASMTL-AS1-overexpressing MDA-MB-231 cells were significantly smaller than those developed from control cells. Further, qRT-PCR results showed that SOX17 was notably increased in ASMTL-AS1-overexpressing tumors, while miR-1228-3p, β-catenin, c-Myc, Cyclin D1, MMP7 and TWIST were significantly decreased (Figure 5C). These suggest that ASMTL-AS1 is a tumor-inhibiting lncRNA that regulates the miR-1228-3p/SOX17/β-catenin axis in vivo, which was in line with in vitro and clinical data.

**Discussion**

Wnt/β-catenin signaling is a well-known oncogenic pathway and frequently abnormally activated in human cancer, including TNBC[16]. However, how it is activated in TNBC is still largely uncertain. In the present study, we found a IncRNA ASMTL-AS1 that negatively regulated Wnt/β-catenin activity via the miR-1228-3p/SOX17 axis. In detail, ASMTL-AS1 acted as a ceRNA that sponged miR-1228-3p and alleviated the binding effect of miR-1228-3p on SOX17 mRNA 3’-UTR, leading to upregulated SOX17, which bound to β-catenin promoter and inhibited β-catenin activation. Pre-clinically, we found that low ASMTL-AS1 was closely related to aggressive clinical features as well as dismal survival, and could be used as a promising prognostic biomarker for TNBC. Therefore, our data highlight the importance of ASMTL-AS1 in inhibiting TNBC development and progression, and also identify a novel regulator of Wnt/β-catenin signaling.

For disease research, biomarkers generally refer to a common physiological or pathological or a certain characteristic biochemical index in the treatment process that can be objectively measured and evaluated[17]. Through the determination of biomarkers, we can know the current biological process of the body. Detection of a disease-specific biomarker may be helpful for disease identification, early diagnosis and prevention, and monitoring in the process of treatment[18]. Thus, discovering valuable biomarkers has become a hot research topic. Very recently, a series of IncRNAs have been reported as cancer biomarkers, such as TP73-AS1 in glioma[19], BGL3 in papillary thyroid carcinoma[20], WT1-AS in lung adenocarcinoma[21], PHACTR2-AS1 in tongue squamous cell carcinoma[22], CRNDE in osteosarcoma[23] and LINC01451 in bladder cancer[24]. Here, we found that ASMTL-AS1 was significantly decreased in TNBC tissues, and patients with low ASMTL-AS1 had poor survival than patients with high ASMTL-AS1 in both our cohort and Kaplan-Meier plotter data. These indicate that ASMTL-AS1 may be a candidate prognostic indicator for TNBC patients. Further studies involving large sample sizes are needed to validate its prognostic value in TNBC, and whether ASMTL-AS1 exists in body fluids, such as sweat, urine, blood or even exosomes, is worthy of further study, which may provide a non-invasive diagnostic biomarker for TNBC.

Recently, ASMTL-AS1 was shown as a key participant in cancer cell biology. Feng et al. reported that ASMTL-AS1 was significantly downregulated in papillary thyroid carcinoma, which served as a tumor suppressor via inhibiting cell growth and glycolysis[13]. However, another study showed that ASMTL-AS1 was an oncoprotein in hepatocellular carcinoma that activated carcinogenic YAP signaling and promoted cancer recurrence or metastasis[14]. Herein, we found that ASMTL-AS1 was a tumor-inhibiting lncRNA in TNBC, inactivating oncogenic Wnt/β-catenin pathway and repressing cell proliferation and invasion, and restoration of ASMTL-AS1 expression significantly retarded the growth of tumor in vivo. The discrepancy of ASMTL-AS1 function in different cancer types can be explained by the cell type- or developmental stage-specific functional pattern of IncRNA[25]. The expression level and functional mechanism of ASMTL-AS1 in other malignant tumors need to be further studied.
Conclusion

Overall, our findings reveal the previously uncharacterized anti-tumor effect of ASMTL-AS1 in TNBC, in which ASMTL-AS1 acts as a ceRNA sponging miR-1228-3p and elevating SOX17, resulting in the inactivation of Wnt/β-catenin signaling, thereby inhibiting TNBC tumorigenesis and progression. Hence, we provide a potential prognostic indicator and therapeutic target for TNBC patients.

Abbreviations

TNBC: Triple-negative breast cancer; LncRNA: long-non coding RNA;
qRT-PCR: Quantitative real-time polymerase chain reaction
miRNA: microRNA
ceRNA: competing endogenous RNA

Declarations

Ethics approval and consent to participate

This work was authorized by the Ethics Committee of The 1st Affiliated Hospital of Soochow University and was carried out according to the guidelines of Declaration of Helsinki. Animal experimental protocols were permitted by the Animal Care and Use Committee of The 1st Affiliated Hospital of Soochow University in accordance with the guidelines of the National Animal Care and Ethics Institution.

Consent for publication

Not applicable.

Availability of data and materials

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

None.

Authors’ contributions

EOY and JXL designed and supervised the study. JS and XHL conducted the experiments and drafted the manuscript. LS conducted the experiments and supervised the study. JS, XHL and QH collected and analyzed the data. QRL contributed the methodology and analyzed the data. All authors read and approved the final manuscript.

Acknowledgement

None.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.
2. Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50.
3. Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019;9(2):176–98.
4. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012;23(9):2223–34.
5. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.
6. Flynn RA, Chang HY. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell. 2014;14(6):752–61.
7. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.
8. Neve B, Jonckheere N, Vincent A, Van Seuningen I. Long non-coding RNAs: the tentacles of chromatin remodeler complexes. Cell Mol Life Sci. 2020.
9. Volovat SR, Volovat C, Hordila I, Hordila DA, Mirestean CC, Miron OT, et al. MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A
10. Mu M, Niu W, Zhang X, Hu S, Niu C. LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway. Oncogene. 2020;39(45):6879–92.

11. Ai D, Yu F. LncRNA DNM3OS promotes proliferation and inhibits apoptosis through modulating IGF1 expression by sponging MiR-126 in CHON-001 cells. Diagn Pathol. 2019;14(1):106.

12. Wang W, Hu W, Wang Y, An Y, Song L, Shang P, et al. Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA. Mol Cancer. 2020;19(1):18.

13. Feng Z, Chen R, Huang N, Luo C. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma. Life Sci. 2020;244:117298.

14. Ma D, Gao X, Liu Z, Lu X, Ju H, Zhang N. Exosome-transferred long non-coding RNA ASMTL-AS1 contributes to malignant phenotypes in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Cell Prolif. 2020;53(9):e12795.

15. Qing L, Gu P, Liu M, Shen J, Liu X, Guang R, et al. Extracellular Matrix-Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer. Onco Targets Ther. 2020;13:12521–38.

16. King TD, Suto MJ, Li Y. The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem. 2012;113(1):13–8.

17. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213–21.

18. Piccoli SP, Garofolo F. Biomarker assay validation. Bioanalysis. 2018;10(12):889–91.

19. Zhang B, Li Q, Wu B, Zhang S, Li L, Jin K, et al. Long non-coding RNA TP73-AS1 is a potential immune related prognostic biomarker for glioma. Aging (Albany NY). 2021;13(1):13–8.

20. Zhao M, Yang F, Sang C, Yan C, Wang Z. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability. J Endocrinol Invest. 2021.

21. Li W, Liu Y, Li ZJ, Shi Y, Deng J, Bai J, et al. Unravelling the Role of LncRNA WT1-AS/miR-206/NAMPT Axis as Prognostic Biomarkers in Lung Adenocarcinoma. Biomolecules. 2021;11(2).

22. Yuan F, Miao Z, Chen W, Wu F, Wei C, Yong J, et al. Long non-coding RNA PHACTR2-AS1 promotes tongue squamous cell carcinoma metastasis by regulating Snail. J Biochem. 2020;168(6):651–7.

23. Yu Y, Wang L, Li Z, Zheng Y, Shi Z, Wang G. Long noncoding RNA CRNDE functions as a diagnostic and prognostic biomarker in osteosarcoma, as well as promotes its progression via inhibition of miR-335-3p. J Biochem Mol Toxicol. 2021:e22734.

24. Shi H, Xie J, Wang K, Li W, Yin L, Wang G, et al. LINC01451 drives epithelial-mesenchymal transition and progression in bladder cancer cells via LIN28/TGF-beta/Smad pathway. Cell Signal. 2021;81:109932.

25. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.

### Tables

**Table 1. Association of ASMTL-AS1 expression with clinical features in 68 triple-negative breast cancer patients**

| Parameters                  | Total (n=68) | ASMTL-AS1 expression | P value |
|-----------------------------|-------------|----------------------|---------|
|                             | Low (n=34)  | High (n=34)          |         |
| Age (years)                 |             |                      |         |
| ≤ 40                        | 21          | 9                    | 12      | 0.431   |
| > 40                        | 47          | 25                   | 22      |         |
| Menopause                   |             |                      |         |
| Yes                         | 28          | 12                   | 16      | 0.324   |
| No                          | 40          | 22                   | 18      |         |
| Tumor size (cm)             |             |                      |         |
| ≤ 2                         | 32          | 8                    | 23      | <0.001  |
| > 2                         | 36          | 25                   | 11      |         |
| Lymph node metastasis       |             |                      |         |
| Negative                    | 25          | 7                    | 18      | 0.006   |
| Positive                    | 43          | 27                   | 16      |         |
| TNM stage                   |             |                      |         |
| I or II                     | 23          | 2                    | 21      | <0.001  |
| III                         | 45          | 32                   | 13      |         |
ASMTL-AS1 is significantly decreased in TNBC. A. The expression of ASMTL-AS1 in GSE45827 database. B. qRT-PCR analysis of ASMTL-AS1 expression in 68 matched TNBC and normal tissues. C. The overall survival curve of TNBC patients with low and high ASMTL-AS1 levels. D-F. The overall, recurrence- or distant metastasis-free survival curve of TNBC patients with low and high ASMTL-AS1 levels in Kaplan-Meier plotter database. ***P<0.001.
Overexpression of ASMTL-AS1 inhibits TNBC cell proliferation and invasion. A. qRT-PCR verifying the overexpression efficiency in two TNBC cells. B, C. The colony rate of TNBC cells after ASMTL-AS1 overexpression. D-G. CCK-8 and Transwell assays testing cell viability and invasion after ASMTL-AS1 overexpression, respectively. **P<0.01.
Figure 3

miR-1228-3p is a target of ASMTL-AS1. A. qRT-PCR analysis of location of ASMTL-AS1 in MDA-MB-213 and MDA-MB-468 cells. B. Three databases predicting miRNAs bound by ASMTL-AS1. C. RNA pull-down assay using ASMTL-AS1 probe, followed by qRT-PCR analysis of miRNA enrichment. D, E. The binding site between ASMTL-AS1 and miR-1228-3p, followed by mutation and luciferase reporter assay. F. qRT-PCR analysis of miR-1228-3p level after ASMTL-AS1 overexpression. **P<0.01.
Figure 4

ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis. A, B. The binding site between SOX17 3’-UTR and miR-1228-3p, followed by mutation and luciferase reporter assay. C, D. qRT-PCR analysis of SOX17 mRNA level after alteration of miR-1228-3p expression. E. Western blotting testing SOX17 and β-catenin protein levels in ASMTL-AS1-overexpressing cells transfected with miR-1228-3p mimics. F. qRT-PCR analysis of β-catenin targets in ASMTL-AS1-overexpressing cells transfected with miR-1228-3p mimics. G, H. CCK-8 and Transwell assays respectively testing cell viability and invasion in ASMTL-AS1-overexpressing cells transfected with miR-1228-3p mimics, SOX17 siRNA or treated with LiCl, a specific activator of Wnt/β-catenin pathway. *P<0.05, **P<0.01.
Figure 5

Recovery of ASMTL-AS1 inhibits tumor growth. A, B. Tumor volume and weight in control and ASMTL-AS1-overexpressing groups. C. qRT-PCR analysis of the indicated gene levels in control and ASMTL-AS1-overexpressing tumors. D. The mechanism diagram showing that ASMTL-AS1 inhibits TNBC progression via the miR-1228-3p/SOX17/Wnt/β-catenin axis.